Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Five Biologic Blockbusters Opened Up To EU Biosimilar Competition In 2017

Jan 09 2018

• By Ian Schofield

Desk — Biosimilar approvals rose sharply in the EU in 2017

Related Content

EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2<sup>nd</sup> Biosimilar Herceptin

Dec 15 2017

CHMP OKs Drugs For MS, Esophagitis, CMV & Hemophilia – And First EU Biosimilar Avastin

Nov 13 2017

28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too

Jan 04 2018

Related Companies

Roche Holding AG

AbbVie Inc.

Amgen, Inc.

Celltrion, Inc.

Novartis AG

Sanofi

STADA Arzneimittel AG

Viatris Inc.

Coherus Oncology, Inc.

FUJIFILM Holdings Corp.

Additional Topics

Europe Biosimilars Approvals Drug Review Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window